Screener
CG Oncology CGON Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Assets | June 30, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Total liabilities | 56,537 | 38,990 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value per share; 700,000,000 and 700,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 88,306,390 and 80,689,128 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 9 | 8 |
| Additional paid-in capital | 1,547,343 | 1,131,570 |
| Accumulated deficit | (518,234) | (378,976) |
| Total stockholders' equity | 1,029,118 | 752,602 |
| Total liabilities and stockholders' equity | $1,085,655 | $791,592 |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's common stock?
- CG Oncology (CGON) reported common stock of $9K in Q2 2026.
- How has CG Oncology's common stock changed year-over-year?
- CG Oncology's common stock increased by 12.5% year-over-year, from $8K to $9K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about CG Oncology's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude